The following is a summary of "ADORA2B promotes proliferation and migration in head and neck squamous cell carcinoma and is ...

The primary endpoint was the mean normalcy of diet score on the clinician-rated Performance Status Scale for Head and Neck at 1 year. The mean score was 91.6 in the dose-reduction arm and 92.6 in the ...

The warm sunshine of spring is a welcome change from the cold and brutal winds of winter in the Upper Midwest. However, with ...

Bicara Therapeutics shows potential to reshape cancer care with ficerafusp alfa and robust funding post-IPO. Find out why ...

New clinical insights support U.S. doctors in using transoral robotic surgery (TORS) to personalize treatment plans for ...

PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today ...

The abstracts will be available on the ASCO® website on May 22, 2025 at 5:00 p.m. ET. The full presentation will be available on the Merus website at the start of the session.

The company will also present a poster on randomized Phase II data of TG4001 in combination with avelumab in the cervical cancer subgroup. The 2025 American Society of Clinical Oncology (ASCO), annual ...

The following is a summary of “Radiologic Imaging Aids Management of High-risk Cutaneous Squamous Cell Carcinoma: A ...

He may only weigh 3 ounces, but this little lizard just helped make veterinary history.Veterinarians at the Smithsonian’s ...

The FDA has granted clearance to an investigational new drug application for CLD-201 for solid tumor treatment, based on ...

ImCheck Announces Oral Presentation of Updated ICT01 Efficacy Data in First-line AML at the ASCO Annual Meeting 2025 ...